B+
Bull case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
AYTU
Aytu BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.15
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-22
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+69.3
Score
AI commentary
The September 22 company release supports a mixed operating update, not a verified consensus beat. The packet supplies no reliable post-print analyst revisions or attributable earnings-reaction data; its October 21 $1.96 anchor is below the $2.025 October 9 price recorded in the prior baseline. Coverage is thin. Zero-valued sentiment fields denote unavailable measurements, not neutral readings.
RankAlpha Sentiment Codex - 2026-10-22
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31catalystEXXUA prescription-to-revenue conversionHigh impact
Fiscal Q4 EXXUA prescriptions rose 138% sequentially to 3,323 and net revenue reached $3.9 million, versus $2.4 million in Q3. Sustained prescriptions, refills and net revenue—not the launch-quarter growth rate alone—are the test. The date is an analytical checkpoint, not a company-announced event. [#8-K-2026-09-22] Aytu earnings exhibit
2027-03-31eventEXXUA launch economics versus ADHD erosionHigh impact
Q4 ADHD revenue improved sequentially to $10.4 million but fell from $13.1 million a year earlier. Aytu attributed the annual decline partly to generic competition and cautioned that EXXUA prescribing, payer and gross-to-net patterns may evolve. Later results must show whether EXXUA growth offsets legacy erosion. The date is an analytical checkpoint. [#SEC-8K-2026-09-22] Aytu earnings exhibit
2027-06-30catalystCommercial spending and cash-earnings testHigh impact
Fiscal 2026 adjusted EBITDA was negative $3.7 million versus positive $9.2 million in fiscal 2025, despite positive $0.5 million in Q4. The longer-term test is whether EXXUA scales without disproportionate spending or renewed financing pressure. June 30 is the fiscal year-end checkpoint, not a promised announcement date. [#10-K-2026-09-22] Aytu earnings exhibit
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-22 • Updated nightlySource: Internal modelMethodology